Heidi Wang

Heidi Wang, Ph.D. is the Chief Executive Officer of OBI Pharma, Inc., a clinical-stage oncology biopharmaceutical company developing novel cancer therapies, including antibody-drug conjugates and immuno-oncology agents. She joined OBI Pharma as CEO in 2023, bringing nearly 30 years of global pharmaceutical leadership and regulatory experience from Bristol-Myers Squibb, where she held senior roles spanning oncology, global regulatory strategy and clinical development. Dr. Wang holds advanced degrees in molecular biology and virology from the University of Notre Dame and completed postdoctoral training at Cold Spring Harbor Laboratory.